Horizon Therapeutics (HZNP) Tops Q1 EPS by 20c; Maintains Outlook
Get Alerts HZNP Hot Sheet
Join SI Premium – FREE
Horizon Therapeutics (NASDAQ: HZNP) reported Q1 EPS of $1.34, $0.20 better than the analyst estimate of $1.14. Revenue for the quarter came in at $885.2 million versus the consensus estimate of $874.41 million.
GUIDANCE:
Horizon Therapeutics maintains its FY2022 revenue outlook of $3.9-4 billion, versus the consensus of $3.98 billion.
For earnings history and earnings-related data on Horizon Therapeutics (HZNP) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Procter & Gamble (PG) revenue falls short of expectations, raises full-year earnings guidance
- Wipro (WIT) Tops Q1 EPS by 1c
- BCB Bancorp (BCBP) Misses Q1 EPS by 2c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!